Partner Content Partner Content Hear from MedImmune and Ipsen at SMi’s Injectable Drug Deliv... Launch of Injectable Drug Delivery
News Ipsen aims for new liver cancer use of Cabometyx Stopping a cancer trial is either a very good, or very bad thing – and luckily for Ipsen the former was the case after a liver cancer trial of its Cabometyx pill was curtailed because of th
Partner Content Partner Content Ipsen presents on oral peptides innovations, advances and de... Ipsen presents on oral peptides innovations & delivery
News NICE wants to axe funding for two thyroid cancer drugs NICE unconvinced by survival data from Ipsen and Sanofi drugs
News CEO Meek looks to boost Ipsen with drug acquisitions Could French biotech snap up remaining rights to pancreatic cancer drug?
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
